Company
Cellmid Limited
Headquarters: Sydney, NSW, Australia
CEO: Ms. Maria Halasz BSc, MBA
Market Cap
A$4.2 Million
AUD as of Jan. 1, 2024
US$2.8 Million
Cellmid Limited Categories
Australia Healthcare BiotechnologyAustralia Healthcare Australia Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Cellmid Limited, a consumer health company, develops, manufactures, and markets anti-aging products for hair, skin, and wellbeing in Australia, the United States, China, and Japan. It develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company markets its products through retailers and wholesalers, as well as through a direct-to-consumer, e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Cellmid Limited has the following listings and related stock indices.
Stock: ASX: CDY wb_incandescent